WNK2 and autosomal dominant polycystic kidney disease: Since ADPKD perturbs the Jnk/Stat (cJun N-terminal kinases/signal transducer and activator of transcription 1), MAPK (mitogen-activated protein kinase), mTOR (mammalian target of rapamycin), Wnt/Wgless (Wingless-related integration site/Wingless)and Erk (extracellular signal regulated kinase) kinase pathways [8], somatostatin analogues, vasopressin receptor antagonists, mTOR inhibitors, and statins have been tested for their ability to ameliorate the course of ADPKD.